Peptide

VIP

Also known as

Vasoactive Intestinal Peptide · Vasoactive Intestinal Polypeptide · Aviptadil (pharmaceutical synthetic VIP) · VIP nasal spray · Intranasal VIP · VIP-CIRS / Shoemaker VIP · Invicorp component (aviptadil + phentolamine ED product — different use/route)

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	Vasoactive intestinal peptide is a natural 28-amino-acid signaling peptide; its synthetic form is called aviptadil.
Mold-illness discussion	Mold-illness communities discuss nasal VIP for brain fog, energy and recovery. Injected, inhaled, IV and erectile-dysfunction products are separate uses.

Notes

VIP is vasoactive intestinal peptide, a natural signaling peptide whose synthetic form is called aviptadil. Mold-illness and CIRS communities discuss nasal VIP for brain fog, energy and recovery after other treatment steps. Reports include striking improvement, no change and substantial worsening; it is not a predictable immune-reset spray.

A 28-amino-acid signaling peptide. VIP carries signals between cells rather than acting like a vitamin or a growth-hormone peptide. CIRS means chronic inflammatory response syndrome; in this discussion it usually refers to persistent symptoms attributed to water-damaged buildings. Shoemaker, House & Ryan: VIP in refractory CIRS-WDB (2013) (Official context · Accessed 2026-09-30)

Nasal CIRS use and injected VIP are different discussions. Nasal spray leads the opened CIRS accounts. SubQ means injection beneath the skin; peptide forums also discuss it. Inhaled or IV aviptadil research and the aviptadil/phentolamine erectile-dysfunction product are separate uses, with different formulations and amounts.

Source context — Shoemaker, House & Ryan: VIP in refractory CIRS-WDB (2013): 20 selected participants; open label, historical healthy comparisons and prior multi-step treatments; not a randomized placebo comparison of DIY VIP.

What people notice

Energy and clarity	One nasal user reports clearer vision, more energy and feeling like themselves, but later still reports worse brain fog and head pressure.
Partial or no benefit	Another describes better concentration with persistent gut problems. Other users report no nasal benefit or flu-like symptoms without later improvement.

Notes

More energy, clearer vision and feeling like themselves. One nasal user described these changes on the first day or within days. Their later update still described worse brain fog and head pressure alongside more energy. These posts are one person's evolving account, not independent successes. VIP is amazing!!! (Personal report · Accessed 2026-09-30) · Over a month on VIP (Community discussion · Accessed 2026-09-30)

Better concentration does not mean every symptom resolves. Another user described cognitive improvement but persistent gut and motility problems. Gut-symptom relief is a separate hope in discussions, not an established consequence of feeling mentally clearer. VIP peptide? (Community discussion · Accessed 2026-09-30) · Digestive system circus and VIP nasal spray, can VIP help? (Community discussion · Accessed 2026-09-30)

No benefit deserves space beside recovery stories. The two-month Phoenix Rising user noticed nothing. Another forum reply also reports no nasal effect. A CIRS user reports major flu-like symptoms without subsequent improvement, despite only three sprays weekly. VIP - Vasoactive intestinal Peptide (Personal report · Accessed 2026-09-30) · Bad reaction to peptide — any thoughts? (Community discussion · Accessed 2026-09-30) · Over a month on VIP (Community discussion · Accessed 2026-09-30)

Source context — VIP is amazing!!!: Same author as Over a month on VIP; one longitudinal story. Dilution ratios in replies do not establish mcg and are deliberately not reproduced as preparation guidance.

Source context — Over a month on VIP: Same positive author as July post; proposed escalation is not actual use. Practitioner and medication changes confound outcome; spray strength unstated.

Source context — VIP peptide?: Narrow anecdotal sample; injection account lacks quantified benefit and dose. Product identity and causation unverified.

Source context — Digestive system circus and VIP nasal spray, can VIP help?: Provider-associated account has commercial context. Early-use discussion establishes a reported practice, not proof of gut efficacy or safety.

Source context — VIP - Vasoactive intestinal Peptide: Dose and prerequisites unknown; author's remembered expense corrected in edit. Access/sourcing replies not reproduced.

Source context — Bad reaction to peptide — any thoughts?: Reply writes 500mg with unclear meaning; dose excluded rather than silently corrected to mcg. Other peptide anecdotes in later replies excluded as unrelated.

Doses people talk about

Nasal chart totals	At the stated 50 mcg per spray, one spray four times daily totals 200 mcg/day; one in each nostril four times daily totals 400 mcg/day. These are different chart patterns.
Lower nasal reports	Older clinic talk includes 50 mcg twice daily for 1–2 weeks. One user reports sleepiness at 50 mcg/day after ten days at 200 mcg/day.
Higher spray counts	One user reports six sprays/day, strength unstated; proposed increases to twelve or twenty-five were plans. Older high-count clinic claims do not establish a safe ceiling.
Under-the-skin chart talk	Separate charts describe 50–100 mcg starts and 100–200 mcg per use once or twice daily. These are not proven equivalents to nasal amounts.

Notes

Nasal charts: 50 mcg per spray; 200 versus 400 mcg/day. The preserved community record describes one spray four times daily versus one in each nostril four times daily. At the stated 50 mcg strength, those mean four versus eight sprays daily. Compounder step-up charts repeat these totals; they are reported practice, not instructions.

Lower nasal amounts are also reported. Older clinic talk includes 50 mcg twice daily for 1–2 weeks. An opened user reports two sprays/day for two weeks, then three, without micrograms. Another describes sleepiness at 50 mcg/day after ten days at 200 mcg/day. Vasoactive intestinal peptide (VIP) experience (Community discussion · Accessed 2026-09-30) · Bratty alert - I simply hate taking VIP/marcons sprays (Community discussion · Accessed 2026-09-30)

Higher counts: actual use and proposed escalation differ. A user reports six sprays/day, with their practitioner proposing 12 and possibly 25. The old record contains clinic-oriented 12- and 24-spray claims for imaging/atrophy goals with lipase monitoring. Neither source establishes a safe ceiling; the user's spray strength is unstated. Over a month on VIP (Community discussion · Accessed 2026-09-30)

SubQ charts: 50–100 mcg starts; 100–200 mcg per use, once or twice daily. The old record also contains 100 mcg/day logs, occasional 200–300 mcg doses and 400 mcg/day totals. These remain distinct from nasal amounts. An opened dosage thread circulates 50–200 mcg per dose, 1–2 times daily, but leaves the route unresolved; its asserted 100 mcg maximum is challenged. VIP dosage (Community discussion · Accessed 2026-09-30)

SubQ vs nasal debate: Some peptide users claim SubQ is “more efficient”; CIRS protocol culture still centers prescription compounded nasal after prerequisites — routes are not proven equivalent. [community]

Source context — Vasoactive intestinal peptide (VIP) experience: Self-report, unspecified spray strengths, differing schedules and concurrent interventions. Some replies collapsed/deleted; no prevalence or mechanism established.

Source context — Bratty alert - I simply hate taking VIP/marcons sprays: 8–10 OP spray count includes multiple products. No established causal explanation or universal protocol rule.

Source context — Over a month on VIP: Same positive author as July post; proposed escalation is not actual use. Practitioner and medication changes confound outcome; spray strength unstated.

Source context — VIP dosage: Route unresolved; quoted advice is not a verified therapeutic standard. No regimen accepted. Exact post date not established from opened relative timestamps.

Half-life, onset & duration

Felt onset	Reports include first-day vision changes, energy after days and concentration gains near two months.
Felt duration	No dependable single-spray benefit window is established. Flushing lasting 5–10 minutes is a separate sensation, with route unclear in that account.
Half-life	Nasal and under-skin values remain unknown here. One small IV study reported blood elimination phases of two and twenty-one minutes, not benefit duration.

Notes

First-day changes in one account; nearly two months in another. One nasal user reports clearer vision on day one and energy after days. Another first noticed substantial concentration/comprehension gains near two months. These are different outcomes. VIP is amazing!!! (Personal report · Accessed 2026-09-30) · Vasoactive intestinal peptide (VIP) experience (Community discussion · Accessed 2026-09-30)

No dependable single-spray benefit window. Accounts mostly follow repeated use. One forum user says energy and clarity receded when stopping because of a rash. That observation does not establish an hours-long duration for everyone. Vasoactive intestinal peptide (VIP) (Community discussion · Accessed 2026-09-30)

Reported flushing lasts 5–10 minutes; worsening can persist much longer. The dosage-thread sensation is distinct from recovery. A Phoenix Rising author describes fragmented sleep and a major setback still present five months after eight days at an increased nasal strength. VIP dosage (Community discussion · Accessed 2026-09-30) · Bad reaction to peptide — any thoughts? (Community discussion · Accessed 2026-09-30)

Around five minutes for flushing in a dosage-thread claim. A commenter describes sensations at 50–100 mcg, with route unclear. Flushing does not prove improved inflammation or oxygen delivery. VIP dosage (Community discussion · Accessed 2026-09-30)

1–2 minutes in blood is a circulated, research-derived claim. A CIRS commenter uses it to argue against SubQ. It is not a measured nasal or SubQ half-life in that user, nor a benefit duration. Those route-specific values remain unknown in these reports. Vasoactive intestinal peptide (VIP) experience (Community discussion · Accessed 2026-09-30)

Blood clearance depends on the experiment. A 1981 IV study in six volunteers reported two elimination phases: 2 and 21 minutes. Neither measures nasal or SubQ persistence. A brief blood half-life cannot be read as a benefit duration. Holm-Bentzen et al.: Infusion of VIP in man (1981) (Official context · Accessed 2026-09-30)

Source context — VIP - Vasoactive intestinal Peptide: Dose and prerequisites unknown; author's remembered expense corrected in edit. Access/sourcing replies not reproduced.

Source context — Over a month on VIP: Same positive author as July post; proposed escalation is not actual use. Practitioner and medication changes confound outcome; spray strength unstated.

Source context — Vasoactive intestinal peptide (VIP): Rash cause and formulation unverified. Older replies contain disputed plasma claims and likely mg/mcg errors; these are not promoted as measurements.

Source context — VIP dosage: Route unresolved; quoted advice is not a verified therapeutic standard. No regimen accepted. Exact post date not established from opened relative timestamps.

Source context — Holm-Bentzen et al.: Infusion of VIP in man (1981): Abstract only; no full-text inspection or nasal/SubQ pharmacokinetics.

Cycles people discuss

Ongoing nasal courses	A three-month plan, two months without benefit and older 4–6-week reassessment or longer-than-twelve-week courses appear; they are different records.
Eight weeks on, eight off	This is a separate forum suggestion without a stated route or outcome, rather than an established optimal break.
Maintenance and refills	Lower-frequency maintenance and restarting after re-exposure are discussed. Product-specific spray expiry is shelf life, not a biological cycle.

Notes

Three months planned; two months with no change also appears. One nasal user plans three months; a forum author noticed no benefit after two. Older provider discussion includes 4–6-week reassessment and imaging courses beyond 12 weeks. Vasoactive intestinal peptide (VIP) experience (Community discussion · Accessed 2026-09-30) · VIP - Vasoactive intestinal Peptide (Personal report · Accessed 2026-09-30)

Eight weeks on/eight off is a separate forum suggestion. A Peptidesource reply proposes this pattern morning and night, without route or outcome. It is not the continuous CIRS replacement pattern and does not establish an optimal break. VIP dosage (Community discussion · Accessed 2026-09-30)

Tapering, restarting and refill blocks vary. Preserved discussion includes lower-frequency maintenance and restarting after re-exposure. Reported 30–60-day spray expiry can shape refill blocks; that is product-specific shelf life, not a biological cycle or universal storage rule.

Source context — VIP - Vasoactive intestinal Peptide: Dose and prerequisites unknown; author's remembered expense corrected in edit. Access/sourcing replies not reproduced.

Source context — VIP dosage: Route unresolved; quoted advice is not a verified therapeutic standard. No regimen accepted. Exact post date not established from opened relative timestamps.

Stacks

Mold-illness treatment combinations	Exposure changes, cholestyramine or Welchol binders and nasal treatments accompany VIP. Accounts disagree about when it fits relative to resistant nasal-staph treatment.
Other peptides	TA-1, LL-37, KPV, Semax/Selank and recovery peptides appear in broader stacks; these accounts do not isolate VIP's effects.

Notes

Exposure and MARCoNS are disputed explanations. MARCoNS is the protocol's term for resistant nasal staphylococci. Older lists emphasize exposure control, binders, a negative culture, improved visual-contrast testing and normal lipase. Opened reports also describe diluted VIP earlier or alongside nasal treatment. That disagreement cannot prove why an individual improves or worsens. Digestive system circus and VIP nasal spray, can VIP help? (Community discussion · Accessed 2026-09-30) · Bratty alert - I simply hate taking VIP/marcons sprays (Community discussion · Accessed 2026-09-30)

Other treatments complicate attribution. The preserved record pairs VIP with exposure changes, cholestyramine/Welchol and nasal treatment, and sometimes TA-1, LL-37, KPV, Semax/Selank or recovery peptides. The July and August positive posts also describe prior treatment and medication changes; none isolates VIP's effect. Over a month on VIP (Community discussion · Accessed 2026-09-30)

Immune peptides (confounded multi-agent): Forums sometimes place VIP near Thymosin Alpha-1, LL-37, or KPV in broader “immune season / biotoxin” kits — attribution to VIP alone is weak. [community]

Nootropic adjacency: Occasional Semax/Selank or other nasal-neuro stacks in biohack threads; evidence for synergy is anecdotal. [anecdote]

Healing-peptide adjacency: BPC-157 / TB-500 / GHK-Cu sometimes run in the same recovery season for injury/inflammation goals — different jobs, heavy confound. [community]

Source context — Bratty alert - I simply hate taking VIP/marcons sprays: 8–10 OP spray count includes multiple products. No established causal explanation or universal protocol rule.

Source context — Over a month on VIP: Same positive author as July post; proposed escalation is not actual use. Practitioner and medication changes confound outcome; spray strength unstated.

Watch for

Worsening symptoms	Anxiety, bloating, fatigue, pain, nasal irritation, rash and migraine are reported. Worse symptoms are not automatically a healing phase.
Prolonged setback	One author describes fragmented sleep and major worsening still present five months after eight days at increased nasal strength.
Lipase concerns	Clinic discussion emphasizes lipase, a pancreatic enzyme, before and during use; monitoring practices do not establish safety or a known pancreatitis rate.
Product strength and stability	Spray calibration, concentration and cold-chain handling matter. Research labeling does not establish equivalence to a prescribed compounded preparation.

Notes

Worse symptoms are not automatically a healing phase. Reports include anxiety, bloating, fatigue, pain, nasal irritation, rash and migraine. One early-use account describes gut trouble on one attempt and a persistent migraine on another. Reports of later improvement do not make prolonged worsening safe to ignore. Bratty alert - I simply hate taking VIP/marcons sprays (Community discussion · Accessed 2026-09-30) · Vasoactive intestinal peptide (VIP) (Community discussion · Accessed 2026-09-30) · VIP nasal spray risks (Personal report · Accessed 2026-09-30)

Lipase monitoring is a major protocol concern. Preserved clinic discussion describes baseline checks, roughly 15-minute first-dose labs, rechecks near two weeks and after increases. Lipase is a pancreatic enzyme; those monitoring practices do not prove safety or a known pancreatitis rate.

Product strength and stability complicate interpretation. The old record notes calibration, concentration and cold-chain concerns. A product labeled for research is not equivalent to a prescribed compounded preparation. Neither a testimonial nor a suspected bad batch verifies contents or explains a reaction.

Source context — Bratty alert - I simply hate taking VIP/marcons sprays: 8–10 OP spray count includes multiple products. No established causal explanation or universal protocol rule.

Source context — VIP nasal spray risks: Unverified attribution and unknown amounts/products, duration not calibrated; cannot estimate event rate.

Source context — VIP dosage: Route unresolved; quoted advice is not a verified therapeutic standard. No regimen accepted. Exact post date not established from opened relative timestamps.

Full notes

What VIP is and why people discuss it

A 28-amino-acid signaling peptide. VIP carries signals between cells rather than acting like a vitamin or a growth-hormone peptide. CIRS means chronic inflammatory response syndrome; in this discussion it usually refers to persistent symptoms attributed to water-damaged buildings. Official context
Nasal CIRS use and injected VIP are different discussions. Nasal spray leads the opened CIRS accounts. SubQ means injection beneath the skin; peptide forums also discuss it. Inhaled or IV aviptadil research and the aviptadil/phentolamine erectile-dysfunction product are separate uses, with different formulations and amounts. Community

What people hope to notice

More energy, clearer vision and feeling like themselves. One nasal user described these changes on the first day or within days. Their later update still described worse brain fog and head pressure alongside more energy. These posts are one person's evolving account, not independent successes. Personal report Reddit / r/CIRS
Better concentration does not mean every symptom resolves. Another user described cognitive improvement but persistent gut and motility problems. Gut-symptom relief is a separate hope in discussions, not an established consequence of feeling mentally clearer. Reddit / r/CIRS Reddit / r/CIRS

Doses people discuss

mcg means micrograms; 1,000 mcg equals 1 mg. These are attributed community amounts, not a regimen.

Nasal charts: 50 mcg per spray; 200 versus 400 mcg/day. The preserved community record describes one spray four times daily versus one in each nostril four times daily. At the stated 50 mcg strength, those mean four versus eight sprays daily. Compounder step-up charts repeat these totals; they are reported practice, not instructions. Community
Lower nasal amounts are also reported. Older clinic talk includes 50 mcg twice daily for 1–2 weeks. An opened user reports two sprays/day for two weeks, then three, without micrograms. Another describes sleepiness at 50 mcg/day after ten days at 200 mcg/day. Community Reddit / r/CIRS Reddit / r/CIRS
Higher counts: actual use and proposed escalation differ. A user reports six sprays/day, with their practitioner proposing 12 and possibly 25. The old record contains clinic-oriented 12- and 24-spray claims for imaging/atrophy goals with lipase monitoring. Neither source establishes a safe ceiling; the user's spray strength is unstated. Reddit / r/CIRS Community
SubQ charts: 50–100 mcg starts; 100–200 mcg per use, once or twice daily. The old record also contains 100 mcg/day logs, occasional 200–300 mcg doses and 400 mcg/day totals. These remain distinct from nasal amounts. An opened dosage thread circulates 50–200 mcg per dose, 1–2 times daily, but leaves the route unresolved; its asserted 100 mcg maximum is challenged. Community Reddit / r/Peptidesource

Half-life

1–2 minutes in blood is a circulated, research-derived claim. A CIRS commenter uses it to argue against SubQ. It is not a measured nasal or SubQ half-life in that user, nor a benefit duration. Those route-specific values remain unknown in these reports. Reddit / r/CIRS

Onset: when people notice a change

First-day changes in one account; nearly two months in another. One nasal user reports clearer vision on day one and energy after days. Another first noticed substantial concentration/comprehension gains near two months. These are different outcomes. Personal report Reddit / r/CIRS
Around five minutes for flushing in a dosage-thread claim. A commenter describes sensations at 50–100 mcg, with route unclear. Flushing does not prove improved inflammation or oxygen delivery. Reddit / r/Peptidesource

Duration: how long effects last

No dependable single-spray benefit window. Accounts mostly follow repeated use. One forum user says energy and clarity receded when stopping because of a rash. That observation does not establish an hours-long duration for everyone. Phoenix Rising ME/CFS Forums
Reported flushing lasts 5–10 minutes; worsening can persist much longer. The dosage-thread sensation is distinct from recovery. A Phoenix Rising author describes fragmented sleep and a major setback still present five months after eight days at an increased nasal strength. Reddit / r/Peptidesource Phoenix Rising ME/CFS Forums

Cycles and course length

Three months planned; two months with no change also appears. One nasal user plans three months; a forum author noticed no benefit after two. Older provider discussion includes 4–6-week reassessment and imaging courses beyond 12 weeks. Reddit / r/CIRS Personal report Community
Eight weeks on/eight off is a separate forum suggestion. A Peptidesource reply proposes this pattern morning and night, without route or outcome. It is not the continuous CIRS replacement pattern and does not establish an optimal break. Reddit / r/Peptidesource
Tapering, restarting and refill blocks vary. Preserved discussion includes lower-frequency maintenance and restarting after re-exposure. Reported 30–60-day spray expiry can shape refill blocks; that is product-specific shelf life, not a biological cycle or universal storage rule. Community

What can go wrong

Worse symptoms are not automatically a healing phase. Reports include anxiety, bloating, fatigue, pain, nasal irritation, rash and migraine. One early-use account describes gut trouble on one attempt and a persistent migraine on another. Reports of later improvement do not make prolonged worsening safe to ignore. Reddit / r/CIRS Phoenix Rising ME/CFS Forums Personal report Community
Lipase monitoring is a major protocol concern. Preserved clinic discussion describes baseline checks, roughly 15-minute first-dose labs, rechecks near two weeks and after increases. Lipase is a pancreatic enzyme; those monitoring practices do not prove safety or a known pancreatitis rate. Community
Product strength and stability complicate interpretation. The old record notes calibration, concentration and cold-chain concerns. A product labeled for research is not equivalent to a prescribed compounded preparation. Neither a testimonial nor a suspected bad batch verifies contents or explains a reaction. Community Community

What the community accounts add

Difficult first weeks can precede improvement, but not in everyone. The four-times-daily author describes anxiety/bloating at one week, difficult first 3–4 weeks, then improvement at six weeks. Another describes months recovering after a full-strength start. Neither predicts everyone's course. Reddit / r/CIRS
Exposure and MARCoNS are disputed explanations. MARCoNS is the protocol's term for resistant nasal staphylococci. Older lists emphasize exposure control, binders, a negative culture, improved visual-contrast testing and normal lipase. Opened reports also describe diluted VIP earlier or alongside nasal treatment. That disagreement cannot prove why an individual improves or worsens. Community Reddit / r/CIRS Reddit / r/CIRS
No benefit deserves space beside recovery stories. The two-month Phoenix Rising user noticed nothing. Another forum reply also reports no nasal effect. A CIRS user reports major flu-like symptoms without subsequent improvement, despite only three sprays weekly. Personal report Phoenix Rising ME/CFS Forums Reddit / r/CIRS
The spray burden can make daily use difficult. One user dislikes repeated sprays and a runny nose; a reply has no such problem. Their 8–10 daily sprays include VIP and MARCoNS products, so that number must not become a VIP dose. Reddit / r/CIRS
Other treatments complicate attribution. The preserved record pairs VIP with exposure changes, cholestyramine/Welchol and nasal treatment, and sometimes TA-1, LL-37, KPV, Semax/Selank or recovery peptides. The July and August positive posts also describe prior treatment and medication changes; none isolates VIP's effect. Community Reddit / r/CIRS

Supporting research, kept separate

A small CIRS series explains much of the protocol lore. The 2013 open-label study followed 20 selected patients for 18 months, starting 50 mcg nasal four times daily after prior treatments. It reported symptom/lab improvement and later reductions in frequency; this does not establish comparable results for unsupervised users. Official context
Blood clearance depends on the experiment. A 1981 IV study in six volunteers reported two elimination phases: 2 and 21 minutes. Neither measures nasal or SubQ persistence. A brief blood half-life cannot be read as a benefit duration. Official context
Migraine research makes headache a material caution. A placebo-controlled experiment used two-hour IV VIP infusions in people with migraine and provoked attacks more often than placebo. This differs from nasal CIRS use and cannot supply its adverse-event rate. Official context